Shots:

• The multicenter survey involves assessing Kesimpta Sensoready autoinjector pen in 80 MS patients and 50 MS nurses- with RMS who received a disease modifying treatment through a subcutaneous/intramuscular injection via an autoinjector
• The result shows MS patients and nurses prefer the Kesimpta Sensoready autoinjector pen over other autoinjectors for current treatment (84% vs 16%). The findings will be presented at the ACTRIMS Forum 2021 on Feb- 2021
• Kesimpta received positive CHMP opinion last month based on two P-III trials showed reduction of annual relapses by over 50% with more than 30% relative risk reduction of 3 mos. CDP vs teriflunomide

 ­ Ref: Novartis | Image: Novartis